Isabella C Glitza Oliva
Overview
Explore the profile of Isabella C Glitza Oliva including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
449
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cottrell T, Lotze M, Ali A, Bifulco C, Capitini C, Chow L, et al.
J Immunother Cancer
. 2025 Mar;
13(3).
PMID: 40054999
Immunotherapy of cancer is now an essential pillar of treatment for patients with many individual tumor types. Novel immune targets and technical advances are driving a rapid exploration of new...
2.
Glitza Oliva I, Palaia J, Sakkal L, Patel D, Moshyk A, Han N, et al.
BMJ Open
. 2025 Jan;
15(1):e091098.
PMID: 39890146
Objective: This study examined real-world treatment patterns and outcomes in patients with melanoma brain metastasis (MBM) treated with first-line immunotherapy consisting of nivolumab plus ipilimumab or anti-programmed death-1 (PD-1) monotherapy...
3.
Esmaeli B, Ogden T, Nichols M, Lu T, Debnam J, Dimitriou F, et al.
Melanoma Res
. 2024 Dec;
35(2):130-144.
PMID: 39656585
Our primary objective was to estimate the overall response rate to immune checkpoint inhibitors (ICIs) in patients with locally advanced, multiply recurrent, or metastatic conjunctival melanoma treated with ICIs. A...
4.
Keatts S, Salem A, Swanson D, Farooqi A, Bishop A, Amaria R, et al.
Clin Transl Radiat Oncol
. 2024 Sep;
49:100856.
PMID: 39308633
Background And Purpose: As patients with advanced melanoma live longer in the context of systemic therapy advancements, better strategies for durable control of bulky tumors are needed. In this study,...
5.
Saberian C, Milton D, Simon J, Amaria R, Diab A, McQuade J, et al.
Neurooncol Pract
. 2024 Jul;
11(4):452-463.
PMID: 39006528
Background: Melanoma leptomeningeal disease (LMD) has a poor prognosis. However, the management of patients with advanced melanoma has evolved with time, including those with LMD. We reviewed a large cohort...
6.
Kim S, Chu Y, Misoi M, Suarez-Almazor M, Tayar J, Lu H, et al.
Nat Commun
. 2024 Jul;
15(1):5621.
PMID: 38965214
No abstract available.
7.
Wilcox J, Chukwueke U, Ahn M, Aizer A, Bale T, Brandsma D, et al.
Neuro Oncol
. 2024 Jun;
26(10):1781-1804.
PMID: 38902944
Leptomeningeal metastases (LM) are increasingly becoming recognized as a treatable, yet generally incurable, complication of advanced cancer. As modern cancer therapeutics have prolonged the lives of patients with metastatic cancer,...
8.
Glitza Oliva I, Ferguson S, Bassett Jr R, Foster A, John I, Hennegan T, et al.
Nat Med
. 2024 Apr;
30(6):1787.
PMID: 38649781
No abstract available.
9.
Nelson B, Roszik J, Ahmed J, Barretto C, Nardo M, Campbell E, et al.
Mol Cancer
. 2024 Mar;
23(1):64.
PMID: 38532456
Previous studies have shown the clinical benefit of rechallenging the RAF pathway in melanoma patients previously treated with BRAF inhibitors. 44 patients with multiple tumors harboring RAF alterations were rechallenged...
10.
Jacques S, McKeown J, Grover P, Johnson D, Zaremba A, Dimitriou F, et al.
Eur J Cancer
. 2024 Jan;
199:113563.
PMID: 38278007
Importance: Acral (AM) and mucosal melanomas (MM) are rare subtypes with a poor prognosis. In those with advanced disease, anti-PD-1 (PD1) therapy has reduced activity compared to that seen in...